Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication - Wikidata - wikimedia - TriplyDB

Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication

Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication

http://www.wikidata.org/entity/Q28324100

about

sameAs

Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1 Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcri [2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analo Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217 Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection The connection domain is implicated in metalloporphyrin binding and inhibition of HIV reverse transcriptase.Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom.Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors.Mutagenicity and pausing of HIV reverse transcriptase during HIV plus-strand DNA synthesis Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients.Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients Development of inhibitors of reverse transcriptase and protease as therapeutics against HIV infection.

P2860

Q27729365-117DDB89-EECD-4AC6-97EE-4467BD9D2A13 Q27735940-1B4B32C3-5D49-45E0-8A5F-CD882FA5B75D Q28316183-554E916C-E875-48EE-8D61-93D29FA9F9D5 Q28318473-AA98BE77-8CFC-42C8-897C-407662811B55 Q28342745-EE5EB7C7-C97B-463F-A0B8-D2EBF2CCDD17 Q28367552-764F6202-F8A7-4869-8C12-D4163D9A68DD Q28367573-8515020A-BE11-4C00-B1D1-2E0B8E23D41C Q28367654-2355036D-9F65-47ED-9F2F-97C29B3C5C26 Q28367759-5709A470-02DA-496B-8523-42A4C42B70C4 Q28368003-3984A1D6-C7F0-443F-8A48-200BE35154B9 Q28368005-4D8A8464-A0E7-4FEB-AEC8-229BD631165A Q28368026-97D49857-8FA6-44E4-A518-01C5D6B8BAB9 Q28368028-F25AE9C5-5810-45BA-B8D4-44B345683404 Q28368032-798C29B2-F45F-4512-B72F-EC8326114141 Q28368034-2BCC02D9-F80A-4521-B04C-046317F34725 Q28368045-227024F1-6B15-4BF7-9D7B-12DAF4E629E5 Q28368053-FA2D7BD2-5F65-4C43-AA26-C40192570C06 Q28368381-E49128F9-B875-49D6-8E03-FE874F33150C Q28376481-D15450A9-251C-473B-9D1B-B66F273331EA Q28378547-795B32F7-04F0-4A23-A631-FDA67A08A2BF Q28378595-05918E4C-3026-47CF-A8B2-0D282E755356 Q28378796-AFD14BD3-6E8F-432E-9FF4-D73044552144 Q28378825-AB92E869-F89A-4468-BC50-675EF78F7E64 Q28378892-F6176EDC-B372-4D4F-9F31-1FEEC6907B48 Q28379002-9F9D4336-E51F-4AE4-895C-EF2F161DF4A5 Q28379406-E1AF8F5A-110F-4050-98C3-DC5ECEAF7FB1 Q28469069-3220C62C-F32F-440A-BE4B-C2B2EA02F4B3 Q28646834-41A91DB9-83E0-4652-A25E-0242485EF224 Q31938029-2F757193-FD53-43A7-A5BD-4176E2DB3B78 Q33813305-58555EC4-74E5-4FEB-8140-F81E0157691F Q34026086-42C12B8F-2936-4EF9-B204-974D4478EBA9 Q34798628-0A4D151D-93E8-464C-9D4D-BC6B5C9A91EF Q35112143-0D1E049A-9C5D-481B-B48F-6356E020E426 Q35122784-8573719F-E407-4A2B-8C12-27AB3654BF55 Q35123292-6B177B66-BD96-498F-8BA0-9F7B633F1462 Q35125592-8176AAA5-3892-4E22-9C81-A888E633E410 Q35129503-272D9488-22DD-4FF0-B073-1D6F0AA73E79 Q35131540-15B03D2C-EA03-4A22-BBCD-E16D8368DA34 Q35137986-8AD7808B-CB6D-440E-A9CB-F894B059A968 Q35174341-0A7998BA-3281-4BAF-BE2A-19B10FB8A600

P2860

Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication

http://www.wikidata.org/entity/Q28324100

description

1991 nî lūn-bûn

@nan

1991 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1991 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

1991年の論文

@ja

1991年論文

@yue

1991年論文

@zh-hant

1991年論文

@zh-hk

1991年論文

@zh-mo

1991年論文

@zh-tw

1991年论文

@wuu

name

Nonnucleoside reverse transcri ...... iency virus type 1 replication

@ast

Nonnucleoside reverse transcri ...... iency virus type 1 replication

@en

Nonnucleoside reverse transcri ...... iency virus type 1 replication

@nl

type

label

Nonnucleoside reverse transcri ...... iency virus type 1 replication

@ast

Nonnucleoside reverse transcri ...... iency virus type 1 replication

@en

Nonnucleoside reverse transcri ...... iency virus type 1 replication

@nl

prefLabel

Nonnucleoside reverse transcri ...... iency virus type 1 replication

@ast

Nonnucleoside reverse transcri ...... iency virus type 1 replication

@en

Nonnucleoside reverse transcri ...... iency virus type 1 replication

@nl

P1433

Q28324100-2716352D-3037-4A0A-A2B6-8CE707861F87

P1476

Q28324100-7E236081-7D90-46A1-997C-82D2B2065AFA

P2093

Q28324100-07E2073D-9A8C-478D-9CAD-CB30C490F0B2

Q28324100-15F04F08-79CF-46E2-99C9-ABE871145790

Q28324100-1689533A-F090-4C14-A335-F8FBFAD64A37

Q28324100-2F366A5D-45A9-4F3D-B600-1B3E350D4BFE

Q28324100-5FEAEA40-C121-43F8-AC07-15B9C0D1C312

Q28324100-6E49DD3F-3E59-43BC-AADF-84BB043923B2

Q28324100-7D85EDA7-6382-4216-8981-605A44F93A2B

Q28324100-94CBEA09-707D-477A-935A-EEC8D3885B5E

Q28324100-C11AECB3-E783-485F-9959-DE6B04B9168E

Q28324100-C22D996B-1AD4-4EC1-9872-EA91D1771AC0

P2860

Q28324100-099CF7FA-5172-4221-8DCA-5A8E9494BB58

Q28324100-1A77B7DA-687A-4A05-8068-72E8C567A250

Q28324100-1F2984E4-F5C1-4447-84E5-D381589F0E91

Q28324100-2E292225-7FD0-4B4C-A0C7-DB4FA646BEBF

Q28324100-36DEDA30-2E03-4610-B1F3-430082774502

Q28324100-4E5ED155-25F0-4B71-B77B-512E8238E065

Q28324100-54FD0FEC-A157-479F-9141-4A36791D6A8E

Q28324100-59F59E9B-1E59-4AF8-BEBA-3227E6660349

Q28324100-603F740F-67F8-4A2D-9E98-66B11EAFC9F7

Q28324100-605040AB-5FA0-4098-9A40-587CAAA3BF68

P304

Q28324100-FBFE5C69-9F1A-47A3-ADBD-3B5489616C25

P31

Q28324100-5C1B0688-7014-4E27-9F73-B50308BE053C

P356

Q28324100-E148F7ED-F1AE-4AE0-9A93-D44777E1E919

P407

Q28324100-5BA60EBF-9B16-4C83-BA6E-F40AFA0E9FB9

P433

Q28324100-191D2035-7E33-4296-A47C-7495902638CF

P478

Q28324100-DB10C193-BD78-49F0-918A-696E73EBD862

P577

Q28324100-EC69ED93-936E-40A5-ACD4-2EE97746DEAE

P5875

Q28324100-331422DB-F70D-4522-B78B-CC0842DB1414

P698

Q28324100-D5C1AE85-CA65-4F92-8418-84D12478A8E5

P932

Q28324100-7F0AEEAE-012E-48F2-A9EA-C3B5D8D40FC2

P356

PNAS.88.19.8806

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Nonnucleoside reverse transcri ...... iency virus type 1 replication

@en

P2093

A G So

http://www.w3.org/2001/XMLSchema#string

C K Tan

http://www.w3.org/2001/XMLSchema#string

D L Romero

http://www.w3.org/2001/XMLSchema#string

F Reusser

http://www.w3.org/2001/XMLSchema#string

J R Palmer

http://www.w3.org/2001/XMLSchema#string

K M Downey

http://www.w3.org/2001/XMLSchema#string

L Resnick

http://www.w3.org/2001/XMLSchema#string

M Busso

http://www.w3.org/2001/XMLSchema#string

P A Aristoff

http://www.w3.org/2001/XMLSchema#string

S M Poppe

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)

A new mammalian DNA polymerase with 3' to 5' exonuclease activity: DNA polymerase delta

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives

Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor

Functional characterization of RNA-dependent DNA polymerase and RNase H activities of a recombinant HIV reverse transcriptase

A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation

Nucleotide dimers suppress HIV expression in vitro

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

P304

8806-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.88.19.8806

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

88

http://www.w3.org/2001/XMLSchema#string

P577

1991-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

21437771

http://www.w3.org/2001/XMLSchema#string

P698

1717988

http://www.w3.org/2001/XMLSchema#string

P932

52599

http://www.w3.org/2001/XMLSchema#string